225 related articles for article (PubMed ID: 34041868)
1. Identification of prognostic and bone metastasis​-related alternative splicing signatures in mesothelioma.
Huang R; Zheng Z; Liu S; Yan P; Song D; Yin H; Hu P; Zhu X; Chang Z; Liu Y; Zhuang J; Meng T; Huang Z; Zhang J
Cancer Med; 2021 Jul; 10(13):4478-4492. PubMed ID: 34041868
[TBL] [Abstract][Full Text] [Related]
2. Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma.
Meng T; Huang R; Zeng Z; Huang Z; Yin H; Jiao C; Yan P; Hu P; Zhu X; Li Z; Song D; Zhang J; Cheng L
Front Bioeng Biotechnol; 2019; 7():270. PubMed ID: 31681747
[No Abstract] [Full Text] [Related]
3. Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma.
Huang R; Yan G; Sun H; Zhang J; Song D; Kong R; Yan P; Hu P; Xie A; Wang S; Zhuang J; Yin H; Meng T; Huang Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32627826
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic and bone metastatic alternative splicing signatures in bladder cancer.
Huang R; Zheng Z; Xian S; Zhang J; Jia J; Song D; Yan P; Yin H; Hu P; Zhu X; Huang Z; Meng T; Zhang J
Bioengineered; 2021 Dec; 12(1):5289-5304. PubMed ID: 34402716
[TBL] [Abstract][Full Text] [Related]
5. The Identification of Prognostic and Metastatic Alternative Splicing in Skin Cutaneous Melanoma.
Huang R; Li M; Zeng Z; Zhang J; Song D; Hu P; Yan P; Xian S; Zhu X; Chang Z; Zhang J; Guo J; Yin H; Meng T; Huang Z
Cancer Control; 2022; 29():10732748211051554. PubMed ID: 34986671
[TBL] [Abstract][Full Text] [Related]
6. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
7. The Construction of Bone Metastasis-Specific Prognostic Model and Co-expressed Network of Alternative Splicing in Breast Cancer.
Huang R; Guo J; Yan P; Zhai S; Hu P; Zhu X; Zhang J; Qiao Y; Zhang Y; Liu H; Huang L; Zhang J; Yang D; Huang Z
Front Cell Dev Biol; 2020; 8():790. PubMed ID: 32984314
[TBL] [Abstract][Full Text] [Related]
8. Germ Cell-Specific Gene 1-Like Protein Regulated by Splicing Factor CUGBP Elav-Like Family Member 5 and Primary Bile Acid Biosynthesis are Prognostic in Glioblastoma Multiforme.
Huang R; Li Z; Li C; Wang G; Yan P; Peng L; Wang J; Zhu X; Hu P; Zhang J; Chang Z; Huang Z; Cheng L; Zhang J
Front Genet; 2019; 10():1380. PubMed ID: 32117422
[TBL] [Abstract][Full Text] [Related]
9. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.
Jiang Y; Zhang C; Chen Y; Zhao S; He Y; He J
Cancer Med; 2023 Feb; 12(4):4895-4906. PubMed ID: 36031798
[TBL] [Abstract][Full Text] [Related]
10. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
[TBL] [Abstract][Full Text] [Related]
11. Identification of Bone Metastatic and Prognostic Alternative Splicing Signatures in Prostate Adenocarcinoma.
Zhu J; Zhang J; Hu P; Fan M; Song D; Yin H; Yan P; Xian S; Li Z; Guo J; Long C; Xu R; Huang R; Meng T; Zhang J; Huang Z
Biochem Genet; 2023 Dec; 61(6):2242-2259. PubMed ID: 37010714
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing events are prognostic in hepatocellular carcinoma.
Chen QF; Li W; Wu P; Shen L; Huang ZL
Aging (Albany NY); 2019 Jul; 11(13):4720-4735. PubMed ID: 31301224
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Bone Metastasis-Associated Immune-Related Genes Regulated by Transcription Factors in Mesothelioma.
Hao Z; Wang S; Zheng Z; Li J; Fu W; Han D; Huang Y; Lin Q; Xian S; Yan P; Li M; Lin R; Meng T; Zhang J; Huang Z
Biomed Res Int; 2022; 2022():9940566. PubMed ID: 35127947
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Wang L; Wang Y; Su B; Yu P; He J; Meng L; Xiao Q; Sun J; Zhou K; Xue Y; Tan J
Sci Rep; 2020 Oct; 10(1):16504. PubMed ID: 33020551
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
16. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
17. Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.
Guo H; Wang S; Xie A; Sun W; Wei C; Xian S; Yin H; Li M; Sun H; Li H; Meng T; Zhang J; Huang Z
Dis Markers; 2021; 2021():1484227. PubMed ID: 34745385
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
19. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
